Gene
RICTOR
RICTOR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (1), Trial mentions (5), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RICTOR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
RICTOR has 5 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 9 of 11,460 | 0.08% |
| 2022 | 0 of 8,285 | 0.00% | 5 of 13,598 | 0.04% |
| 2021 | 1 of 8,692 | 0.01% | 6 of 15,045 | 0.04% |
| 2020 | 0 of 7,640 | 0.00% | 5 of 14,459 | 0.03% |
| 2019 | 0 of 7,300 | 0.00% | 6 of 12,159 | 0.05% |
| 2018 | 2 of 6,927 | 0.03% | 11 of 11,854 | 0.09% |
| 2017 | 2 of 6,558 | 0.03% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | No clinical or analytical validation recorded for this pair | 2 | April 01, 2015 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RICTOR amplification | Mtorc1/2 Inhibitors | response-associated | lung carcinoma | Cancer Genome Interpreter |
Trial mentions (5)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03452774 | Trial eligibility (AACT) |
| NCT03061708 | Trial eligibility (AACT) |
| NCT04518137 | Trial eligibility (AACT) |
| NCT03106155 | Trial eligibility (AACT) |
| NCT03166904 | Trial eligibility (AACT) |
Target-disease associations (265)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Arrhythmia | phenotype | Literature (Europe PMC) |
| Atypical Endometrial Hyperplasia | cancer or benign tumor | Cancer Gene Census |
| Atypical Meningioma | cancer or benign tumor | Cancer Gene Census |
| B-cell acute lymphoblastic leukemia | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 265 associations.
Vendor sourcing (14)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.3007G>T (p.V1003L) alteration is located in exon 30 (coding exon 30) of the RICTOR gene. This alteration results from a G to T substitution at nucleoti... | View ClinVar record SCV003551235.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | \] * Provision of informed consent prior to any study specific procedures * Men and women aged at least 18 years * Small cell lung cancer harboring RICTOR a... | View trial NCT03106155 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | RICTOR | View trial NCT03106155 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 1007 of the RICTOR protein (p.Asp1... | View ClinVar record SCV007395859.1 |
| Massive Bio, Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, ... | View trial NCT03452774 |
Showing 5 of 14 sourcing records.
Trial-cited literature (91)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. | Frontiers in endocrinology | 2023 | 212 |
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Research progress in the role and mechanism of Leucine in regulating animal growth and development. | Frontiers in physiology | 2023 | 59 |
| Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment. | Cells | 2023 | 42 |
| Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium. | International journal of molecular sciences | 2023 | 31 |
Showing 5 of 91 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.H442R | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (7)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| EVEROLIMUS | Chemical | negative_correlate |
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. | 2021 |
| Sirolimus | Chemical | associate |
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. | 2009 |
| Sirolimus | Chemical | associate |
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | 2007 |
| Adenocarcinoma | Disease | associate |
Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. | 2018 |
| Small Cell Lung Carcinoma | Disease | associate |
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. | 2014 |
Showing 5 of 7 relation assertions.
Organizations publishing (115)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 5 | 2009 to 2018 |
| Dana-Farber Cancer Institute | Other | 4 | 2009 to 2019 |
| Government of the United States of America | Government | 3 | 2014 to 2018 |
| McLaren Health Care | Hospital | 3 | 2019 to 2021 |
| Memorial Sloan Kettering Cancer Center | Hospital | 3 | 2017 to 2021 |
Showing 5 of 115 organizations.
Where RICTOR appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- urinary system disease
251 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.